Sara Tolaney· @stolaney1 · X·· 2 天前评分70
正文 · 机器翻译
DESTINY-Breast05：TDXd 治疗残余 HER2+ 疾病
TDXd + T-DM1 两种治疗均维持了 HRQOL
与 T-DM1 相比，TDXd 与疼痛及手臂症状恶化所需时间更长相关
@OncoAlert #ESMO26
502 浏览 · 7 赞 · 4 转发 · 0 回复
会议摘要
539RO按 Rapid oral: Breast cancer, early stage 对上
Patient-reported outcomes (PROs) from DESTINY-Breast05: Health-related quality of life (HRQoL) with trastuzumab Deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (Pts) with high-risk HER2-positive early breast cancer (eBC)
https://esmocongress.esmo.org来源：Sara Tolaney · x.com